BusinessHospital Administration

California Stem Cell Company Takes Over Hoag Hospital Cancer Program

1 Mins read

The company is focused on working with stem cells and also has another division that creates tools for predictive toxicology screening, in other words drug imagescreening.  The company also has partnerships with Johns Hopkins

The company is focused on working with stem cells and also has another division that creates tools for predictive toxicology screening, in other words drug imagescreening.  The company also has partnerships with Johns Hopkins, UC Irvine and a few other healthcare organizations. 

California Stem Cell (CSC) is a privately held company focused on the manufacture of high-purity human cells for therapeutic development and clinical application.  CSC is currently developing stem cell based therapies for spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s Disease).”

This particular treatment seeks out the the worst type of melanoma and destroy the cells that break away from the initial tumor and are found elsewhere in the body.  This is the first time the company has acquired a treatment program that was developed at a hospital.  BD 

An Irvine stem-cell company is taking charge of a Hoag Hospital cancer program that trains its patients’ own immune systems to attack tumors.

The program, acquired by California Stem Cell Inc., specializes in treating malignant skin cancer by targeting the stem cells of the cancer itself — that is, the part of a cancerous tumor that is active and growing.

Hoag Memorial Hospital Presbyterian has been developing the treatment over the past 20 years.

The patient’s own tumor stem cells, as well as immune cells, are purified from their blood.

The immune cells are then “taught” to recognize the cancer stem cells, and injected back into the patient’s body.

The treatment targets the worst type of skin cancer, malignant melanoma. And it can seek out and destroy “seed” cells that break away from the initial tumor and lie dormant elsewhere in the body — out of reach of traditional cancer treatments.

UC Irvine researcher Hans Keirstead, who developed the first human embryonic stem-cell treatment for spinal cord injuries to be tested on patients, is chairman of the company’s science advisory board, Airress said.

The company also has applied to the U.S. Food and Drug Administration to begin a treatment for spinal muscular atrophy, a disease that typically kills its victims in their first years of life.

 

Related posts
BusinessMarketing

The Most Effective Instagram Features and Apps for Your Successful Healthcare Video Marketing

6 Mins read
The global healthcare industry is worth over $9 trillion, and many healthcare companies leverage Instagram’s social network reach to promote their brands,…
BusinessHospital Administration

Pre-Med Majors: How to Best Prepare for Medical School

2 Mins read
Whether you wish to be a doctor, surgeon, medical consultant or dentist, or pursue any other medical profession, the preparation should start…
BusinessHospital Administration

Hospital Recruitment Tweaks to Help You Hire More Qualified Applicants

2 Mins read
Even when restrictions and the number of in-patient cases is bound to subside as the COVID-19 vaccines are distributed to the public,…